Login to Your Account

Dynogen's GI, GU Products To Benefit From $50M Round

By Karen Pihl-Carey

Tuesday, April 20, 2004
In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical compounds. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription